

Nancy L Bartlett

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1662737/nancy-l-bartlett-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

354
papers

20,597
citations

61
h-index

140
g-index

375
ext. papers

25,228
ext. citations

5.3
avg, IF

6.34
L-index

| # | Paper | IF | Citations |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 354 | Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 2531-2544 | 59.2 | 2326 |
| 353 | Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2183-9 | 2.2 | 1091 |
| 352 | Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. <i>New England Journal of Medicine</i> , 2010 , 363, 1812-21 | 59.2 | 1079 |
| 351 | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 2425-37 | 59.2 | 950 |
| 350 | Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2453-63 | 2.2 | 936 |
| 349 | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 31-42 | 21.7 | 796 |
| 348 | Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1396-1407 | 59.2 | 780 |
| 347 | Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2190-6 | 2.2 | 759 |
| 346 | CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 379, 1711-1721 | 59.2 | 456 |
| 345 | Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018 , 379, 2517-2528 | 59.2 | 455 |
| 344 | Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 378, 331-344 | 59.2 | 378 |
| 343 | Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. <i>Molecular Therapy</i> , 2017 , 25, 285-295 | 11.7 | 370 |
| 342 | Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncology, The</i> , 2016 , 17, 200-211 | 21.7 | 314 |
| 341 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 229-240 | 40 | 283 |
| 340 | Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. <i>Blood</i> , 2002 , 99, 4336-42 | 2.2 | 235 |
| 339 | Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. <i>Journal of Clinical Oncology</i> , 2002 , 20, 630-7 | 2.2 | 233 |
| 338 | Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood</i> , 2014 , 123, 3095-100 | 2.2 | 224 |

| | | | |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 337 | A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2009 , 146, 171-9 | 4.5 | 213 |
| 336 | Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013 , 31, 684-91 | 2.2 | 204 |
| 335 | Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2018 , 131, 1183-1194 | 2.2 | 203 |
| 334 | Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. <i>Cancer</i> , 2010 , 116, 106-14 | 6.4 | 194 |
| 333 | A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. <i>Clinical Cancer Research</i> , 2012 , 18, 248-55 | 12.9 | 190 |
| 332 | Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. <i>Blood</i> , 2015 , 125, 1394-402 | 2.2 | 185 |
| 331 | US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2020-7 | 2.2 | 184 |
| 330 | A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. <i>Blood</i> , 2008 , 111, 1848-54 | 2.2 | 168 |
| 329 | Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2018 , 379, 934-947 | 59.2 | 168 |
| 328 | Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6101-8 | 2.2 | 166 |
| 327 | Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. <i>Blood</i> , 2003 , 101, 4285-92 | 2.2 | 162 |
| 326 | Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. <i>Blood</i> , 2012 , 120, 3280-7 | 2.2 | 159 |
| 325 | Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1790-1799 | 2.2 | 156 |
| 324 | A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. <i>Blood</i> , 2011 , 118, 5119-25 | 2.2 | 152 |
| 323 | Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 39, 181-94 | 7 | 148 |
| 322 | Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 692-700 | 2.2 | 145 |
| 321 | Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). <i>Journal of Clinical Oncology</i> , 2015 , 33, 3635-40 | 2.2 | 139 |
| 320 | 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 386-92 | 8.9 | 133 |

| | | | |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 319 | Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3137-43 | 2.2 | 127 |
| 318 | Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). <i>Blood</i> , 2015 , 126, 851-7 | 2.2 | 124 |
| 317 | Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. <i>Blood</i> , 2017 , 130, 2709-2717 | 2.2 | 121 |
| 316 | Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 24 | 22.4 | 119 |
| 315 | Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. <i>Blood</i> , 2019 , 134, 6-6 | 2.2 | 105 |
| 314 | Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013 , 121, 3547-53 | 2.2 | 102 |
| 313 | Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. <i>Blood</i> , 2017 , 129, 473-483 | 2.2 | 98 |
| 312 | The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. <i>Clinical Cancer Research</i> , 2016 , 22, 596-608 | 12.9 | 97 |
| 311 | Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. <i>Lancet Haematology</i> , 2018 , 5, e609-e617 | 14.6 | 96 |
| 310 | Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. <i>Journal of Clinical Oncology</i> , 2000 , 18, 972-80 | 2.2 | 93 |
| 309 | Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018 , 131, 182-190 | 2.2 | 92 |
| 308 | The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013 , 161, 76-86 | 4.5 | 86 |
| 307 | Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1620-5 | 2.2 | 84 |
| 306 | Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2399-404 | 2.2 | 82 |
| 305 | Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018 , 103, 1502-1510 | 6.6 | 82 |
| 304 | Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 912-8 | 2.2 | 82 |
| 303 | A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. <i>Cancer</i> , 2012 , 118, 3128-34 | 6.4 | 80 |
| 302 | Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. <i>Cancer Discovery</i> , 2018 , 8, 1258-1269 | 24.4 | 78 |

| | | | |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 301 | Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1646-52 | 4.7 | 76 |
| 300 | Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. <i>British Journal of Haematology</i> , 2017 , 179, 739-747 | 4.5 | 73 |
| 299 | Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. <i>Blood</i> , 2016 , 128, 469-469 | 2.2 | 73 |
| 298 | Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. <i>Lancet Haematology</i> , 2017 , 4, e176-e182 | 14.6 | 66 |
| 297 | Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. <i>Lancet Oncology</i> , 2019 , 20, 998-1010 | 21.7 | 66 |
| 296 | Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3217-22 | 2.2 | 65 |
| 295 | Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 350-7 | 8.9 | 64 |
| 294 | Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4132-9 | 2.2 | 63 |
| 293 | CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018 , 132, 1013-1021 | 2.2 | 59 |
| 292 | Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1797-803 | 2.2 | 59 |
| 291 | A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 44 | 22.4 | 59 |
| 290 | Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1313-9 | 1.9 | 57 |
| 289 | CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. <i>Blood</i> , 2020 , 136, 2308-2318 | 2.2 | 55 |
| 288 | A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). <i>European Journal of Cancer</i> , 2016 , 54, 11-17 | 7.5 | 55 |
| 287 | Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020 , 135, 735-742 | 2.2 | 54 |
| 286 | Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015 , 90, 778-83 | 7.1 | 53 |
| 285 | A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2016 , 22, 1059-66 | 12.9 | 52 |
| 284 | Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. <i>Blood</i> , 2011 , 117, 5314-20 | 2.2 | 52 |

| | | | |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 283 | Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019 , 134, 1238-1246 | 2.2 | 50 |
| 282 | Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2143-50 | 1.9 | 45 |
| 281 | Assessment of knowledge about cancer pain management by physicians in training. <i>Journal of Pain and Symptom Management</i> , 1997 , 14, 21-8 | 4.8 | 45 |
| 280 | Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. <i>Blood</i> , 2016 , 128, 2510-2516 | 2.2 | 45 |
| 279 | Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2328-34 | 1.9 | 40 |
| 278 | Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2283-6 | 1.9 | 40 |
| 277 | Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2519-2529 | 2.2 | 39 |
| 276 | Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. <i>Blood</i> , 2018 , 131, 2120-2124 | 2.2 | 39 |
| 275 | Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015 , 171, 530-8 | 4.5 | 39 |
| 274 | CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. <i>American Journal of Clinical Pathology</i> , 2014 , 141, 381-7 | 1.9 | 39 |
| 273 | Hodgkin lymphoma. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 61 | 51.1 | 39 |
| 272 | High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1345-9 | 1.9 | 38 |
| 271 | Anti-CD30 Antibodies for Hodgkin lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2010 , 5, 140-7 | 4.4 | 38 |
| 270 | Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. <i>Blood</i> , 2018 , 132, 399-399 | 2.2 | 38 |
| 269 | A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2020 , 136, 2401-2409 | 2.2 | 38 |
| 268 | Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020 , 135, 2224-2234 | 2.2 | 37 |
| 267 | Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. <i>Blood</i> , 2020 , 135, 2106-2109 | 2.2 | 37 |
| 266 | Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. <i>Blood</i> , 2014 , 124, 395-395 | 2.2 | 37 |

| | | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|
| 265 | Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation. <i>American Journal of Surgical Pathology</i> , 1998 , 22, 1255-66 | 6.7 | 37 |
| 264 | Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. <i>Oncologist</i> , 2012 , 17, 1073-80 | 5.7 | 36 |
| 263 | A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. <i>Blood</i> , 2019 , 133, 1201-1204 | 2.2 | 35 |
| 262 | Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2015 , 6, 211-8 | 3.6 | 35 |
| 261 | Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1607-1616 | 1.9 | 35 |
| 260 | Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018 , 124, 136-144 | 6.4 | 34 |
| 259 | Brentuximab vedotin for the treatment of CD30+ lymphomas. <i>Immunotherapy</i> , 2011 , 3, 475-85 | 3.8 | 34 |
| 258 | Bone marrow staging in patients with non-Hodgkin's lymphoma: is flow cytometry a useful test?. <i>Cancer</i> , 1998 , 82, 1154-9 | 6.4 | 33 |
| 257 | Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3003-3011 | 2.2 | 33 |
| 256 | Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 450-6 | 2.2 | 32 |
| 255 | Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 234-234 | 2.2 | 32 |
| 254 | Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). <i>Leukemia and Lymphoma</i> , 2015 , 56, 958-64 | 1.9 | 31 |
| 253 | Progressive multifocal leukoencephalopathy treated with nivolumab. <i>Journal of NeuroVirology</i> , 2019 , 25, 284-287 | 3.9 | 30 |
| 252 | Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3025-3025 | 2.2 | 30 |
| 251 | Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. <i>Cancer</i> , 2001 , 92, 207-17 | 6.4 | 28 |
| 250 | Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202. <i>Blood</i> , 2014 , 124, 3091-3091 | 2.2 | 28 |
| 249 | Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. <i>British Journal of Haematology</i> , 2014 , 165, 510-8 | 4.5 | 27 |
| 248 | Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. <i>Blood</i> , 2020 , 136, 42-44 | 2.2 | 27 |

| | | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|
| 247 | Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. <i>Blood</i> , 2021 , 138, 427-438 | 2.2 | 27 |
| 246 | Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2569-78 | 1.9 | 26 |
| 245 | Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas.. <i>Blood</i> , 2008 , 112, 1006-1006 | 2.2 | 26 |
| 244 | Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial. <i>Blood</i> , 2014 , 124, 800-800 | 2.2 | 26 |
| 243 | Blinatumomab for the treatment of B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 715-24 | 5.9 | 25 |
| 242 | Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. <i>Cancer</i> , 2014 , 120, 2122-9 | 6.4 | 25 |
| 241 | A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. <i>Leukemia and Lymphoma</i> , 2011 , 52, 587-96 | 1.9 | 25 |
| 240 | Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003 , 18, 165-78 | 3.9 | 25 |
| 239 | Serum Markers in Germ Cell Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 1991 , 5, 1245-1260 | 6.0 | 25 |
| 238 | A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas. <i>Blood</i> , 2013 , 122, 848-848 | 2.2 | 25 |
| 237 | Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1936-42 | 2.2 | 24 |
| 236 | Intravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature. <i>American Journal of Medicine</i> , 1999 , 107, 169-76 | 2.4 | 24 |
| 235 | Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. <i>Blood</i> , 2016 , 128, LBA-6-LBA-6 | 2.2 | 24 |
| 234 | Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2017 , 178, 250-256 | 4.5 | 22 |
| 233 | Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. <i>Journal of the National Cancer Institute</i> , 2017 , 109, | 9.7 | 22 |
| 232 | Cyclin D1 as an aid in the diagnosis of mantle cell lymphoma in skin biopsies: a case report. <i>American Journal of Dermatopathology</i> , 2001 , 23, 470-6 | 0.9 | 22 |
| 231 | A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. <i>Blood</i> , 2016 , 128, 998-998 | 2.2 | 22 |
| 230 | Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020 , 4, 858-867 | 7.8 | 21 |

| | | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 229 | The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). <i>Leukemia and Lymphoma</i> , 2013 , 54, 1405-10 | 1.9 | 21 |
| 228 | Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. <i>British Journal of Haematology</i> , 2008 , 140, 313-9 | 4.5 | 21 |
| 227 | Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. <i>Blood</i> , 2015 , 126, 337-337 | 2.2 | 21 |
| 226 | First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 Non-Hodgkin Lymphomas. <i>Clinical Cancer Research</i> , 2020 , 26, 2524-2534 | 12.9 | 20 |
| 225 | Modern treatment of Hodgkin lymphoma. <i>Current Opinion in Hematology</i> , 2008 , 15, 408-14 | 3.3 | 20 |
| 224 | Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2013 , 122, 1809-1809 | 2.2 | 20 |
| 223 | Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7512-7512 | 2.2 | 20 |
| 222 | Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology,the</i> , 2021 , 8, e410-e421 | 14.6 | 20 |
| 221 | Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019 , 25, 1718-1726 | 12.9 | 20 |
| 220 | Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019 , 133, 1762-1765 | 2.2 | 19 |
| 219 | Interdigitating dendritic reticulum cell tumor of lymph nodes: case report with differential diagnostic considerations. <i>Diagnostic Cytopathology</i> , 2003 , 28, 278-81 | 1.4 | 19 |
| 218 | A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 347-353 | 2 | 19 |
| 217 | Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604). <i>Blood</i> , 2015 , 126, 578-578 | 2.2 | 18 |
| 216 | A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 875-82 | 4.1 | 18 |
| 215 | Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary. <i>Journal of Clinical Oncology</i> , 2013 , 31, e443-5 | 2.2 | 17 |
| 214 | The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.. <i>Blood</i> , 2009 , 114, 2731-2731 | 2.2 | 17 |
| 213 | CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 601-611 | 5.9 | 17 |
| 212 | Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7504-7504 | 2.2 | 16 |

| | | | |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 211 | Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology, the</i> , 2020 , 7, e808-e815 | 14.6 | 16 |
| 210 | Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1191-3 | 1.9 | 15 |
| 209 | Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. <i>Therapeutic Advances in Hematology</i> , 2014 , 5, 3-12 | 5.7 | 15 |
| 208 | Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100931 | 2.3 | 15 |
| 207 | Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 1105-1105 | 2.2 | 15 |
| 206 | Role of routine imaging in lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 575-84; quiz 585 | 7.3 | 15 |
| 205 | The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. <i>Cancer Medicine</i> , 2019 , 8, 165-173 | 4.8 | 15 |
| 204 | CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. <i>American Journal of Transplantation</i> , 2021 , 21, 809-814 | 8.7 | 15 |
| 203 | Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012 , 53, 506-7 | 1.9 | 13 |
| 202 | Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies. <i>Cancer</i> , 2002 , 95, 2223-9 | 6.4 | 13 |
| 201 | Antibodies for the treatment of diffuse large cell lymphoma. <i>Seminars in Oncology</i> , 2003 , 30, 448-56 | 5.5 | 13 |
| 200 | Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2019 , 133, 416 | 2.2 | 13 |
| 199 | Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. <i>Blood</i> , 2019 , 134, 238-238 | 2.2 | 13 |
| 198 | Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2014 , 124, 3095-3095 | 2.2 | 13 |
| 197 | Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 1092-1106 | 7.3 | 13 |
| 196 | Therapy of relapsed Hodgkin lymphoma. <i>Blood Reviews</i> , 2007 , 21, 233-43 | 11.1 | 12 |
| 195 | A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. <i>Blood</i> , 2018 , 132, 1620-1620 | 2.2 | 12 |
| 194 | Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 194, 690-700 | 4.5 | 12 |

| | | | |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|
| 193 | Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. <i>Blood</i> , 2018 , 131, 1698-1703 | 2.2 | 11 |
| 192 | Drug development for recurrent and refractory classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 529-40 | 1.9 | 11 |
| 191 | PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. <i>Blood</i> , 2019 , 134, 349-349 | 2.2 | 11 |
| 190 | Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkin Disease (NLPHD).. <i>Blood</i> , 2007 , 110, 644-644 | 2.2 | 11 |
| 189 | Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2010 , 116, 961-961 | 2.2 | 11 |
| 188 | Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R. <i>Blood</i> , 2015 , 126, 342-342 | 2.2 | 11 |
| 187 | Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7518-7518 | 2.2 | 11 |
| 186 | Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016 , 91, 894-9 | 7.1 | 11 |
| 185 | Parameters for Validating a Hospital Pneumatic Tube System. <i>Clinical Chemistry</i> , 2019 , 65, 694-702 | 5.5 | 10 |
| 184 | Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1151-3 | 1.9 | 10 |
| 183 | High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1202-5 | 1.9 | 10 |
| 182 | Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2005 , 2005, 245-51 | 3.1 | 10 |
| 181 | SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).. <i>Blood</i> , 2006 , 108, 2718-2718 | 2.2 | 10 |
| 180 | A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Blood</i> , 2010 , 116, 415-415 | 2.2 | 10 |
| 179 | Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. <i>Blood</i> , 2011 , 118, 443-443 | 2.2 | 10 |
| 178 | NCCN Guidelines Insights: B-Cell Lymphomas, Version 5.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 1218-1230 | 7.3 | 10 |
| 177 | Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. <i>Blood Advances</i> , 2021 , 5, 4149-4155 | 7.8 | 10 |
| 176 | Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. <i>Blood</i> , 2015 , 125, 3354-5 | 2.2 | 9 |

| | | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|---|
| 175 | Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin Disease.. <i>Blood</i> , 2004 , 104, 2635-2635 | 2.2 | 9 |
| 174 | A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.. <i>Blood</i> , 2006 , 108, 2727-2727 | 2.2 | 9 |
| 173 | A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. <i>Blood</i> , 2009 , 114, 3693-3693 | 2.2 | 9 |
| 172 | Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.. <i>Blood</i> , 2010 , 116, 2800-2800 | 2.2 | 9 |
| 171 | A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2012 , 120, 55-55 | 2.2 | 9 |
| 170 | Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2016 , 128, 104-104 | 2.2 | 9 |
| 169 | A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma. <i>Blood</i> , 2016 , 128, 150-150 | 2.2 | 9 |
| 168 | Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3188-3197 | 1.9 | 9 |
| 167 | Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. <i>Lancet Haematology,the</i> , 2020 , 7, e490-e497 | 14.6 | 8 |
| 166 | Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?. <i>Current Hematologic Malignancy Reports</i> , 2012 , 7, 179-85 | 4.4 | 8 |
| 165 | Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL). <i>Blood</i> , 2008 , 112, 371-371 | 2.2 | 8 |
| 164 | Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015 , 126, 3991-3991 | 2.2 | 8 |
| 163 | Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016 , 128, 4144-4144 | 2.2 | 8 |
| 162 | Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. <i>American Journal of Hematology</i> , 2020 , 95, 583-593 | 7.1 | 7 |
| 161 | Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution. <i>Hematology American Society of Hematology Education Program</i> , 2017 , 2017, 317-323 | 3.1 | 7 |
| 160 | Composite diffuse large B-cell lymphoma and precursor B lymphoblastic lymphoma presenting as a double-hit lymphoma with MYC and BCL2 translocation. <i>Journal of Clinical Pathology</i> , 2011 , 64, 1032-4 | 3.9 | 7 |
| 159 | Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1511-7 | 1.9 | 7 |
| 158 | Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),. <i>Blood</i> , 2011 , 118, 3711-3711 | 2.2 | 7 |

| | | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|---|
| 157 | A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.. <i>Blood</i> , 2012 , 120, 2746-2746 | 2.2 | 7 |
| 156 | Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3339-3350 | 12.9 | 7 |
| 155 | Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study. <i>Leukemia and Lymphoma</i> , 2018 , 59, 357-362 | 1.9 | 6 |
| 154 | Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 2199-2204 | 4.7 | 6 |
| 153 | Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 793-8 | 3.5 | 6 |
| 152 | MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices. <i>Cancer</i> , 1993 , 71, 4034-42 | 6.4 | 6 |
| 151 | Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502. <i>Blood</i> , 2008 , 112, 232-232 | 2.2 | 6 |
| 150 | A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. <i>Blood</i> , 2008 , 112, 2595-2595 | 2.2 | 6 |
| 149 | Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. <i>Blood</i> , 2012 , 120, 60-60 | 2.2 | 6 |
| 148 | Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation. <i>Blood</i> , 2015 , 126, 2726-2726 | 2.2 | 6 |
| 147 | ABVD plus rituximab ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. <i>Haematologica</i> , 2019 , 104, e65-e67 | 6.6 | 6 |
| 146 | Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. <i>Blood</i> , 2021 , | 2.2 | 6 |
| 145 | Salvage regimens for Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 517-240.6 | 6 | 6 |
| 144 | Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL) 2018 , | | 5 |
| 143 | Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study. <i>Blood</i> , 2018 , 132, 1647-1647 | 2.2 | 5 |
| 142 | Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. <i>Blood</i> , 2018 , 132, 929-929 | 2.2 | 5 |
| 141 | Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2007 , 110, 1351-1351 | 2.2 | 5 |
| 140 | A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2012 , 120, 1623-1623 | 2.2 | 5 |

| | | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---|
| 139 | A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2012 , 120, 1644-1644 | 2.2 | 5 |
| 138 | The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013 , 122, 3060-3060 | 2.2 | 5 |
| 137 | Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. <i>Blood</i> , 2013 , 122, 4386-4386 | 2.2 | 5 |
| 136 | Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up. <i>Blood</i> , 2015 , 126, 1537-1537 | 2.2 | 5 |
| 135 | A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 3988-3988 | 2.2 | 5 |
| 134 | Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study. <i>Blood</i> , 2016 , 128, 1853-1853 | 2.2 | 5 |
| 133 | SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial. <i>Blood</i> , 2016 , 128, 2974-2974 | 2.2 | 5 |
| 132 | Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2016 , 128, 2993-2993 | 2.2 | 5 |
| 131 | Limited-Stage Hodgkin Lymphoma: Optimal Chemotherapy and the Role of Radiotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 33, 374-380 | 7.1 | 5 |
| 130 | Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016 , 24, 383-91 | 1.9 | 5 |
| 129 | Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). <i>Cancer</i> , 2019 , 125, 3378-3389 | 6.4 | 4 |
| 128 | Biologic agents in the management of Hodgkin lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 587-96 | 7.3 | 4 |
| 127 | Treatment advances in non-Hodgkin's lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2000 , 1, 451-66 | 4 | 4 |
| 126 | Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). <i>Blood</i> , 2018 , 132, 1635-1635 | 2.2 | 4 |
| 125 | Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018 , 132, 2904-2904 | 2.2 | 4 |
| 124 | Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.. <i>Blood</i> , 2009 , 114, 2726-2726 | 2.2 | 4 |
| 123 | Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). <i>Blood</i> , 2010 , 116, 4882-4882 | 2.2 | 4 |
| 122 | Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. <i>Blood</i> , 2014 , 124, 1745-1745 | 2.2 | 4 |

| | | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---|
| 121 | Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. <i>Blood</i> , 2014 , 124, 629-629 | 2.2 | 4 |
| 120 | Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. <i>Blood</i> , 2015 , 126, 814-814 | 2.2 | 4 |
| 119 | Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8506-8506 | 2.2 | 4 |
| 118 | Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7541-7541 | 2.2 | 4 |
| 117 | Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 831-839 | 5.4 | 3 |
| 116 | Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e532-e535 | 2 | 3 |
| 115 | Protein losing enteropathy associated with follicular lymphoma of the small bowel. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009 , 32, 222-3 | 2.7 | 3 |
| 114 | The present: optimizing therapy--too much or too little?. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 108-14 | 3.1 | 3 |
| 113 | Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08). <i>Blood</i> , 2018 , 132, 2964-2964 | 2.2 | 3 |
| 112 | Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. <i>Blood</i> , 2018 , 132, 2892-2892 | 2.2 | 3 |
| 111 | The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). <i>Blood</i> , 2019 , 134, 1591-1591 | 2.2 | 3 |
| 110 | Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.. <i>Blood</i> , 2006 , 108, 2737-2737 | 2.2 | 3 |
| 109 | A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009 , 114, 586-586 | 2.2 | 3 |
| 108 | Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. <i>Blood</i> , 2011 , 118, 1603-1603 | 2.2 | 3 |
| 107 | Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. <i>Blood</i> , 2011 , 118, 94-94 | 2.2 | 3 |
| 106 | Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. <i>Blood</i> , 2012 , 120, 2745-2745 | 2.2 | 3 |
| 105 | A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL). <i>Blood</i> , 2014 , 124, 3099-3099 | 2.2 | 3 |
| 104 | Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance). <i>Blood</i> , 2015 , 126, 2741-2741 | 2.2 | 3 |

| | | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|---|
| 103 | Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance). <i>Blood</i> , 2016 , 128, 2953-2953 | 2.2 | 3 |
| 102 | Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8003-8003 | 2.2 | 3 |
| 101 | Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥ Prior Lines of Therapy: Pivotal Results from a Phase I/II Study. <i>Blood</i> , 2021 , 138, 127-127 | 2.2 | 3 |
| 100 | Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. <i>Lancet Haematology</i> , 2021 , 8, e818-e827 | 14.6 | 3 |
| 99 | Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 384-393 | 6.7 | 3 |
| 98 | Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. <i>OncoTargets and Therapy</i> , 2016 , 9, 2027-34 | 4.4 | 3 |
| 97 | SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 81-90 | 2 | 2 |
| 96 | Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: A teaching case. <i>Practical Radiation Oncology</i> , 2017 , 7, e23-e26 | 2.8 | 2 |
| 95 | Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. <i>Blood</i> , 2018 , 132, 2927-2927 | 2.2 | 2 |
| 94 | Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. <i>Blood</i> , 2019 , 134, 1524-1524 | 2.2 | 2 |
| 93 | Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens. <i>Blood</i> , 2010 , 116, 1753-1753 | 2.2 | 2 |
| 92 | Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. <i>Blood</i> , 2010 , 116, 416-416 | 2.2 | 2 |
| 91 | Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?.. <i>Blood</i> , 2011 , 118, 3644-3644 | 2.2 | 2 |
| 90 | Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies. <i>Blood</i> , 2012 , 120, 3687-3687 | 2.2 | 2 |
| 89 | Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013 , 122, 4277-4277 | 2.2 | 2 |
| 88 | Lack Of Clinical Benefit For Routine Surveillance Imaging For Diffuse Large B-Cell Lymphoma In First Complete Remission. <i>Blood</i> , 2013 , 122, 4303-4303 | 2.2 | 2 |
| 87 | Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. <i>Blood</i> , 2015 , 126, 2936-2936 | 2.2 | 2 |
| 86 | Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401). <i>Blood</i> , 2015 , 126, 331-331 | 2.2 | 2 |

| | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|---|
| 85 | Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015 , 126, 495-495 | 2.2 | 2 |
| 84 | Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. <i>Blood</i> , 2015 , 126, 574-574 | 2.2 | 2 |
| 83 | PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy. <i>Blood</i> , 2016 , 128, 610-610 | 2.2 | 2 |
| 82 | Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7537-7537 | 2.2 | 2 |
| 81 | The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089/NCT03038672).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS7570-TPS7570 | 2.2 | 2 |
| 80 | Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021 , 138, 639-639 | 2.2 | 2 |
| 79 | Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701. <i>Blood</i> , 2021 , 138, 523-523 | 2.2 | 2 |
| 78 | Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 1585-1585 | 2.2 | 2 |
| 77 | Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. <i>Blood</i> , 2011 , 118, 2686-2686 | 2.2 | 2 |
| 76 | Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021 , 35, 2854-2861 | 10.7 | 2 |
| 75 | Management of advanced stage Hodgkin's lymphoma. <i>Cancer Treatment and Research</i> , 2006 , 131, 333-523.5 | | 2 |
| 74 | To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2019 , 25, 1027-1030 ¹ | | 1 |
| 73 | Approaches to aggressive B-cell lymphomas in less fit patients. <i>Hematology American Society of Hematology Education Program</i> , 2020 , 2020, 140-147 | 3.1 | 1 |
| 72 | The justification of vincristine dose capping: tradition, tradition, tradition!. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1007-1009 | 1.9 | 1 |
| 71 | Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle. <i>Journal of Clinical Oncology</i> , 2020 , 38, 662-668 | 2.2 | 1 |
| 70 | Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 374-80 | 7.1 | 1 |
| 69 | Treatment of aggressive histology lymphoma. <i>Current Opinion in Oncology</i> , 1997 , 9, 413-9 | 4.2 | 1 |
| 68 | Hodgkin's disease: prognostic factors and short-course regimens. <i>Current Oncology Reports</i> , 2000 , 2, 163-71 | 6.3 | 1 |

| | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---|
| 67 | Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2020 , 136, 3-4 | 2.2 | 1 |
| 66 | The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018 , 132, 997-997 | 2.2 | 1 |
| 65 | End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2020 , 136, 30-31 | 2.2 | 1 |
| 64 | Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009 , 114, 3417-3417 | 2.2 | 1 |
| 63 | Pralatrexate Reverses the Trend to Progressive Resistance to Successive Systemic Treatment Regimens In Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL). <i>Blood</i> , 2010 , 116, 4881-4881 | 2.2 | 1 |
| 62 | A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma [a Correlative Study From the E2496 Intergroup Trial. <i>Blood</i> , 2011 , 118, 430-430 | 2.2 | 1 |
| 61 | Toxicities and Related Outcomes of Elderly Patients (pts) (≥5 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611). <i>Blood</i> , 2016 , 128, 536-536 | 2.2 | 1 |
| 60 | Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7559-7559 | 2.2 | 1 |
| 59 | Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6). <i>Blood</i> , 2021 , 138, 2832-2832 | 2.2 | 1 |
| 58 | The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 135-135 | 2.2 | 1 |
| 57 | Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance. <i>Blood</i> , 2021 , 138, 2417-2417 | 2.2 | 1 |
| 56 | Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study. <i>Blood</i> , 2021 , 138, 3573-3573 | 2.2 | 1 |
| 55 | Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015 , 126, 2730-2730 | 2.2 | 1 |
| 54 | Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS7566-TPS7566 | 2.2 | 1 |
| 53 | Defining the Malignant Epigenome in Non-Hodgkin Lymphoma. <i>Blood</i> , 2012 , 120, 524-524 | 2.2 | 1 |
| 52 | A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2223-2228 | 4.7 | 1 |
| 51 | Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2408-2415 | 1.9 | 1 |
| 50 | A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 486-488 | 1.9 | 1 |

| | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|---|
| 49 | Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021 , 5, 3623-3632 | 7.8 | 1 |
| 48 | Treatment of nodular lymphocyte-predominant Hodgkin lymphoma-"do no harm". <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 385-7 | 0.6 | 1 |
| 47 | Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. <i>Blood</i> , 2020 , 136, 35-36 | 2.2 | 1 |
| 46 | Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2442-2447 | 1.9 | 0 |
| 45 | Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.. <i>Blood</i> , 2006 , 108, 2429-2429 | 2.2 | 0 |
| 44 | Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8038-8038 | 2.2 | 0 |
| 43 | Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2014 , 124, 4461-4461 | 2.2 | 0 |
| 42 | Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis. <i>Blood</i> , 2015 , 126, 2636-2636 | 2.2 | 0 |
| 41 | Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS7571-TPS7571 | 2.2 | 0 |
| 40 | Protect our children: Hodgkin lymphoma survivors. <i>Blood</i> , 2021 , 137, 1433-1434 | 2.2 | 0 |
| 39 | CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma. <i>Lancet, The</i> , 2021 , 398, 1109-1110 | 4.0 | 0 |
| 38 | Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3097-3103 | 2.2 | 0 |
| 37 | Highlights in lymphoma from the 2013 American Society of Hematology Annual Meeting and Exposition: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12 Suppl 6, 18-23 | 0.6 | 0 |
| 36 | COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.. <i>Leukemia and Lymphoma</i> , 2022 , 1-5 | 1.9 | 0 |
| 35 | Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 1-13 | 1.9 | 0 |
| 34 | Reply to T.M. Weis et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2953 | 2.2 | |
| 33 | A Young Woman With Blurred Vision and Distal Paresthesias. <i>JAMA Neurology</i> , 2015 , 72, 1519-23 | 17.2 | |
| 32 | Management of Classical Hodgkin Lymphoma 2014 , 227-234 | | |

| | | |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 31 | Solid, low-attenuation splenic lesions on computed tomography in patients with indolent lymphoma often signal transformation: a series of ten patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 452-4 | 2 |
| 30 | ⁹⁰ Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2004 , 4, 1323-31 | 5-4 |
| 29 | Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]. <i>Blood</i> , 2020 , 136, 50-50 | 2.2 |
| 28 | Patient-Specific Metabolism Assessed By Visceral Fat and Diabetes May Alter Prognosis in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 30-31 | 2.2 |
| 27 | Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress). <i>Blood</i> , 2021 , 138, 3564-3564 | 2.2 |
| 26 | Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R. <i>Blood</i> , 2021 , 138, 453-453 | 2.2 |
| 25 | Novel Genetic Subgroups Inform on Shared Pathobiology within Adult and Pediatric Burkitt Lymphoma. <i>Blood</i> , 2021 , 138, 806-806 | 2.2 |
| 24 | A Phase II Study of Xcellerated T Cells In Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2004 , 104, 4640-4640 | 2.2 |
| 23 | Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results. <i>Blood</i> , 2018 , 132, 2929-2929 | 2.2 |
| 22 | Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. <i>Blood</i> , 2018 , 132, 2878-2878 | 2.2 |
| 21 | Impact of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 4203-4203 | 2.2 |
| 20 | Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. <i>Blood</i> , 2019 , 134, 4027-4027 | 2.2 |
| 19 | Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas. <i>Blood</i> , 2019 , 134, 1550-1550 | 2.2 |
| 18 | Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq. <i>Blood</i> , 2019 , 134, 1492-1492 | 2.2 |
| 17 | North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 1553-1553 | 2.2 |
| 16 | Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. <i>Blood</i> , 2014 , 124, 1703-1703 | 2.2 |
| 15 | Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 3961-3961 | 2.2 |
| 14 | Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN. <i>Blood</i> , 2015 , 126, 1539-1539 | 2.2 |

- 13 Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). *Blood*, **2015**, 126, 2938-2938 2.2
- 12 Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. *Blood*, **2016**, 128, 4403-4403 2.2
- 11 Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.. *Blood*, **2008**, 112, 1460-1460 2.2
- 10 Clonal Ig DNA Detection In Plasma From Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). *Blood*, **2010**, 116, 3127-3127 2.2
- 9 Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) [Interim Analysis]. *Blood*, **2010**, 116, 1397-1397 2.2
- 8 Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. *Blood*, **2012**, 120, 4779-4779 2.2
- 7 Lymphoma Surveillance Counterpoint: USA **2013**, 461-466
- 6 Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients. *Blood*, **2013**, 122, 1785-1785 2.2
- 5 Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era. *Blood*, **2013**, 122, 847-847 2.2
- 4 Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.. *Journal of Clinical Oncology*, **2021**, 39, 7528-7528 2.2
- 3 Advances in LLM: Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. *Clinical Advances in Hematology and Oncology*, **2012**, 10, 468-71 0.6
- 2 Commentary. *Clinical Advances in Hematology and Oncology*, **2014**, 12, 18-23 0.6
- 1 Radiation for early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a double-edged sword?. *Leukemia and Lymphoma*, **2016**, 57, 249-251 1.9